Development of AAV Episome-Based Nonviral Vectors for Prolonged Gene Expression in Hemophilia A - Development of AAV Episome-Based Nonviral Vectors for Prolonged Gene Expression in Hemophilia A Abstract Hemophilia A (HA) is a promising target for gene therapy. Gene therapy can be mediated by either viral or nonviral vectors. Among these, adeno-associated virus (AAV) can facilitate long-term gene expression, the recent approval of Roctavian (AAV5) for adult HA patients represents a signiflcant milestone in the fleld. However, due to its limited packaging capacity, all AAV based FVIII gene therapies use the B domain deleted FVIII (FVIII-BDD), which is not natural and may trigger inhibitor development and result in declined therapeutic effect. In addition, AAV-based gene therapies can’t be used in patients with pre-existing AAV neutralizing antibodies and can’t be redosed. In contrast, nonviral vectors do not have such limitations but are hindered by their durability. An ideal gene therapy product would combine the strengths of both AAV and non-viral vectors: accommodating large genes, safely mediating long-term gene expression, and allowing for re-dosing when necessary. Currently, no such vector exists. Over the decades, efforts to improve nonviral vector durability have achieved limited success. One potential strategy involves Ʋanking the gene of interest with AAV Inverted Terminal Repeats (ITRs), which shows some promise, however, the results are not as impressive as expected. Recently, we demonstrated for the flrst time that, following AAV delivery, ITR-mediated recombination produces a variety of episomal intermediates, accompanied by differential epigenetic histone modifications resulting in differential genome fate in vivo. The persistent AAV episomes possess specific molecular features at both genetic and epigenetic levels. Building on this new understanding, we are now developing a strategy to graft these molecular features into nonviral episomal vectors to improve durability. Noteworthy, our preliminary studies demonstrated that incorporating one of the consensus-like recombinant intermediates into non-viral vectors, with flreƲy luciferase as a reporter, and delivering as a close end linear DNA conflguration sustained gene expression for over two months in vivo (by the time of writing this proposal, still ongoing). This provides proof of concept and strongly supports the feasibility to develop novel nonviral vectors with introduction of sequences from AAV recombinants for long term and stable transgene expression. In Phase I, we will flrst analyze the stable episomes from the ongoing treated mice following the non-viral delivery, select the most persistent intermediates and evaluate the persistence in vitro and phenotype correction in hemophilia A disease model. The distinction between our current approach and past work by ourselves and others is that we capture stable intermediates that persist in the liver following viral and non-viral delivery. Our present data demonstrated that these intermediates generate a distinctive structure characterized by two fused ITRs, forming double D junctions with selected deletions and mutations—an aspect that has not been looked at thoroughly by anyone else. We propose utilization of the most persistent intermediates to develop durable circular non-viral vectors. If successful, this approach is particularly well-suited for gene therapies for hemophilia A pediatric patients and other diseases that require larger transgenes and may require repeated dosing.